Catalent's New Acquisition will Expand High-Potent Capabilities, Oral Manufacturing Capacity: Report

• Catalent Inc (NYSE: CTLT) agreed to acquire Metrics Contract Services, a full-service specialty Contract Development and Manufacturing Organization, for $475 million from Mayne Pharma Group Limited.

• Upon completion, the acquisition will strengthen Catalent's integrated oral solid formulation development, manufacturing, and packaging capabilities.

• The deal will also expand Catalent's capacity to handle highly potent compounds.

• Metrics Contract operates a 333,000-square-foot facility in Greenville, North Carolina. It includes 16 manufacturing suites, with 11 designed to handle highly potent compounds and two packaging lines.

• The facility's estimated annual production capacity exceeds one billion oral solid dose units.

• The acquisition is expected to close before the end of 2022, and a team of over 400 employees will join Catalent.

• Mayne Pharma and Catalent have also agreed on a long-term supply agreement whereby the Greenville facility will continue manufacturing multiple Mayne Pharma products.

• Catalent held cash & cash equivalents of $786 million at the end of the March quarter.

• Price Action: CTLT shares closed at $108.13 on Tuesday.

See more from Benzinga

• SAB Biotherapeutics Shifts Focus On Infection Candidate As DoD Contract Closes

• Halozyme Therapeutics Shares Jump On Better Than Expected Annual Guidance

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.